43975-308 : Cyclophosphamide 50 mg Oral Capsule


NDC: 43975-308
Labeler: Amerigen Pharmaceuticals Inc.
Product Type: Human Prescription Drug
Drug Name:  Cyclophosphamide
Dosage Form: Oral Capsule
Application #: ANDA207014
Rev. Date: 


Appearance:


Markings: AMG;308
Shapes:  Capsule
Colors:  Green
Size (mm): 20
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 43975-308-10: 100 CAPSULE IN 1 BOTTLE (43975‑308‑10)

Active Ingredients:

  • Cyclophosphamide

Dosage Strength:

  • 50 mg

Inactive Ingredients:

  • Starch, Corn
  • Titanium Dioxide
  • Isopropyl Alcohol
  • Gelatin, Unspecified
  • Shellac
  • Sodium Stearyl Fumarate
  • Propylene Glycol
  • Methyl Alcohol
  • D&c Yellow No. 10
  • Fd&c Blue No. 1
  • Fd&c Blue No. 2
  • Fd&c Green No. 3
  • Fd&c Red No. 40
  • Ferrosoferric Oxide
  • Alcohol
  • Butyl Alcohol /

Pharmaceutical Classes:

  • Alkylating Activity [MoA]
  • Alkylating Drug [EPC]

Related Products:

Based on records with the same trade name.
  • 43975-307 Cyclophosphamide 25 mg Oral Capsule by Amerigen Pharmaceuticals Inc.
  • 0054-0382 Cyclophosphamide 25 mg Oral Capsule by Roxane Laboratories, Inc.
  • 0054-0383 Cyclophosphamide 50 mg Oral Capsule by Roxane Laboratories, Inc.
  • 0054-4129 Cyclophosphamide 25 mg Oral Tablet by Roxane Laboratories, Inc
  • 0054-4130 Cyclophosphamide 50 mg Oral Tablet by Roxane Laboratories, Inc
  • 0781-3233 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 0781-3244 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 0781-3255 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 10019-935 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-936 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-937 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-938 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-939 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-942 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-943 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-944 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-945 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-955 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-956 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-957 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 43975-308 QR Code

< Prev: 43975-307Next: 43975-309 >

Related Discussions:

greyhound cyclophosphamide with pirixicam cyl hycl 100 cap
My Greyhound Cut his Foot And He Takes Cyclophosphamide 17 Mg With Pirixicam 11 mg once A Day with food. I Want To Know ...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.